A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels

Sponsor:

AVEO Pharmaceuticals, Inc.

Sponsor Study ID:

AV-380-22-102

CTO #:

103743

NCT Number:

NCT05865535

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Colon; Pancreas

Study Objectives:

To refine the dose and schedule of AV-380 and establish its adverse event (AE), pharmacokinetic (PK), and pharmacodynamic (PD) profile in metastatic cancer patients with cachexia and elevated GDF-15, receiving SoC chemotherapy for metastatic cancer

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)